Stoke Therapeutics (STOK) Retained Earnings (2018 - 2026)

Stoke Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$115000.0 for Q1 2026.

• In Q1 2026, Retained Earnings rose 99.97% year-over-year to -$115000.0; the TTM figure through Mar 2026 stood at -$115000.0 (up 99.97% YoY), while the FY2025 annual figure was $543000.0, down 99.92% from the prior year.
• Retained Earnings for Q1 2026 stood at -$115000.0, down from $543000.0 in the prior quarter.
• The five-year high for Retained Earnings was $720.0 million in Q4 2024, with the low at -$439.8 million in Q3 2025.
• The 5-year median for Retained Earnings is -$24000.0 (2023), against an average of $54.1 million.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings sank 1233968.18% in 2022, then soared 3000087.5% in 2024.
• Stoke Therapeutics' Retained Earnings stood at -$1.2 million in 2022, then soared by 97.96% to -$24000.0 in 2023, then jumped by 3000087.5% to $720.0 million in 2024, then plunged by 99.92% to $543000.0 in 2025, then plunged by 121.18% to -$115000.0 in 2026.
• Business Quant data shows STOK's Retained Earnings at -$115000.0 in Q1 2026, $543000.0 in Q4 2025, and -$439.8 million in Q3 2025.